SCHEMBL20928593

SCHEMBL20928593

CC(C)c1cc(-c2ccc(F)cc2C(C)C)on1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2RL1 P55085 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ CHRNA1 P02708 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ POLB P06746 1/20 0.33
▸ PIK3CD O00329 2/20 0.33
▸ PIK3CB P42338 2/20 0.33
▸ PIK3CG P48736 2/20 0.33
▸ ACKR3 P25106 2/20 0.33
▸ MTOR P42345 1/20 0.33
▸ MAPK10 P53779 2/20 0.33
▸ MAPK14 Q16539 2/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ CSNK1D P48730 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20929017 0.87 NPC1 (0.37) F2RL1NPC1RAB9ASMN1; SMN2GRM5
SCHEMBL23083141 0.82 PTPRB (0.41) F2RL1NPC1RAB9ASMN1; SMN2GRM5
SCHEMBL20928891 0.80 CHRNA1 (0.37) NPC1RAB9ASMN1; SMN2GRM5CHRNA1
SCHEMBL8223425 0.80 F2RL1 (0.46) F2RL1NPC1RAB9ASMN1; SMN2MAPK10
SCHEMBL24092059 0.75 RPS6KB1 (0.50) F2RL1SMN1; SMN2GRM5CSF1RALDH1A1
SCHEMBL25854731 0.75 HDAC3 (0.44) NPC1RAB9ASMN1; SMN2GRM5CHRNA1
SCHEMBL20928596 0.74 SMN1; SMN2 (0.42) NPC1RAB9ASMN1; SMN2HRH4POLB
SCHEMBL20928602 0.74 HRH4 (0.35) HRH4
SCHEMBL20928887 0.72 MAOA (0.38) NPC1RAB9ASMN1; SMN2HRH4POLB
SCHEMBL20928601 0.72 UTRN (0.34) HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound TOKYO OHKA KOGYO CO., LTD. (JP) 2021-06-01 — — US disclosed
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND TOKYO OHKA KOGYO CO., LTD. (JP) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190121233-A1 CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PHOTOSENSITIVE DRY FILM, METHOD OF MANUFACTURING PATTERNED RESIST FILM, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, METHOD OF MANUFACTURING PLATED ARTICLE, AND MERCAPTO COMPOUND CUTA, POLR1C, ASIC1 F2RL1 1063/4885NPC1 4878/4885RAB9A 1924/4885
US-11022880-B2 Chemically amplified positive-type photosensitive resin composition, photosensitive dry film, method of manufacturing photosensitive dry film, method of manufacturing patterned resist film, method of manufacturing substrate with template, method of manufacturing plated article, and mercapto compound CUTA, POLR1C, ASIC1 F2RL1 1063/4885NPC1 4878/4885RAB9A 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback